Christopher Robert Manz, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prisoners | 2 | 2023 | 297 | 1.350 |
Why?
|
| Neoplasms | 17 | 2024 | 21683 | 1.250 |
Why?
|
| Communication | 8 | 2023 | 3749 | 1.130 |
Why?
|
| Terminal Care | 2 | 2023 | 1694 | 0.700 |
Why?
|
| Prospective Payment System | 1 | 2020 | 133 | 0.690 |
Why?
|
| Biomedical Technology | 1 | 2020 | 220 | 0.620 |
Why?
|
| Medicare | 5 | 2024 | 6566 | 0.620 |
Why?
|
| Equipment and Supplies | 1 | 2020 | 281 | 0.610 |
Why?
|
| Drug Therapy | 1 | 2020 | 497 | 0.590 |
Why?
|
| Life Expectancy | 1 | 2020 | 1184 | 0.470 |
Why?
|
| Reimbursement Mechanisms | 1 | 2019 | 670 | 0.460 |
Why?
|
| Outpatients | 1 | 2020 | 1486 | 0.440 |
Why?
|
| Benchmarking | 1 | 2019 | 1042 | 0.430 |
Why?
|
| Marketing | 1 | 2014 | 212 | 0.430 |
Why?
|
| Physicians | 2 | 2024 | 4567 | 0.400 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2019 | 1270 | 0.380 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2023 | 2020 | 0.380 |
Why?
|
| Advance Care Planning | 3 | 2022 | 662 | 0.360 |
Why?
|
| Drug Industry | 1 | 2014 | 746 | 0.320 |
Why?
|
| Death | 2 | 2023 | 678 | 0.320 |
Why?
|
| Medical Oncology | 5 | 2023 | 2265 | 0.320 |
Why?
|
| Telemedicine | 1 | 2022 | 2872 | 0.250 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 20822 | 0.230 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 9239 | 0.220 |
Why?
|
| Quality of Life | 2 | 2023 | 12804 | 0.210 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 5137 | 0.210 |
Why?
|
| United States | 7 | 2024 | 69872 | 0.200 |
Why?
|
| Humans | 29 | 2024 | 744343 | 0.200 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 6773 | 0.200 |
Why?
|
| Prisons | 1 | 2023 | 161 | 0.190 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 13102 | 0.170 |
Why?
|
| Social Justice | 1 | 2023 | 456 | 0.160 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 13695 | 0.160 |
Why?
|
| Electronic Health Records | 1 | 2014 | 4468 | 0.150 |
Why?
|
| Patient Care Planning | 1 | 2023 | 921 | 0.150 |
Why?
|
| Palliative Care | 2 | 2023 | 3493 | 0.150 |
Why?
|
| Economics, Hospital | 1 | 2019 | 213 | 0.150 |
Why?
|
| Female | 13 | 2023 | 380194 | 0.140 |
Why?
|
| Tamoxifen | 1 | 2019 | 981 | 0.120 |
Why?
|
| Diffusion of Innovation | 1 | 2019 | 725 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 9959 | 0.120 |
Why?
|
| Administration, Oral | 1 | 2021 | 3913 | 0.120 |
Why?
|
| Hospice Care | 1 | 2020 | 672 | 0.110 |
Why?
|
| Inappropriate Prescribing | 1 | 2014 | 202 | 0.100 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2023 | 1634 | 0.100 |
Why?
|
| Accidental Falls | 1 | 2019 | 1062 | 0.100 |
Why?
|
| Aged | 6 | 2024 | 163280 | 0.100 |
Why?
|
| Health Promotion | 1 | 2023 | 2205 | 0.100 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2019 | 1524 | 0.100 |
Why?
|
| Lymphoma | 1 | 2019 | 1877 | 0.090 |
Why?
|
| Medication Adherence | 1 | 2021 | 2063 | 0.090 |
Why?
|
| Middle Aged | 7 | 2023 | 213383 | 0.090 |
Why?
|
| Health Status Disparities | 1 | 2021 | 1797 | 0.090 |
Why?
|
| Early Detection of Cancer | 1 | 2023 | 3086 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2022 | 40561 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2021 | 10252 | 0.080 |
Why?
|
| Male | 7 | 2023 | 350118 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2022 | 53288 | 0.070 |
Why?
|
| Algorithms | 3 | 2022 | 13881 | 0.070 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 3229 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 3143 | 0.070 |
Why?
|
| Databases, Factual | 1 | 2021 | 7729 | 0.070 |
Why?
|
| Pharmaceutical Preparations | 1 | 2014 | 1071 | 0.070 |
Why?
|
| Prognosis | 3 | 2022 | 29063 | 0.070 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 3158 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 9274 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 2023 | 6364 | 0.060 |
Why?
|
| Pancreatic Neoplasms | 1 | 2023 | 5256 | 0.060 |
Why?
|
| Prevalence | 1 | 2021 | 15226 | 0.060 |
Why?
|
| Quality of Health Care | 1 | 2019 | 4371 | 0.060 |
Why?
|
| Incidence | 1 | 2021 | 20947 | 0.060 |
Why?
|
| Mucin 5AC | 1 | 2023 | 93 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2021 | 77449 | 0.050 |
Why?
|
| Pandemics | 1 | 2022 | 8388 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 57776 | 0.030 |
Why?
|
| Documentation | 1 | 2021 | 871 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2023 | 1708 | 0.030 |
Why?
|
| Triage | 1 | 2021 | 976 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 5319 | 0.020 |
Why?
|
| Phenotype | 1 | 2022 | 16365 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 15076 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 11524 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2019 | 23338 | 0.010 |
Why?
|
| Adult | 1 | 2023 | 214055 | 0.010 |
Why?
|